EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy

DaQuan Wang, SongRan Liu, Jia Fu, PengXin Zhang, ShiYang Zheng, Bo Qiu, Hui Liu, YongQuan Ye, JinYu Guo, Yin Zhou, HaiHang Jiang, ShaoHan Yin und 3 weitere

Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e008574

DOI: 10.1136/jitc-2023-008574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 23.06.2024. Verfasst von DaQuan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinica…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate the prognostic significance of pretreatment dynamic contrast-enhanced (DCE)-MRI parameters concerning tumor response following induction immunochemotherapy and survival outcomes in patients with locally advanced non-small cell lung cancer (NSCLC) who underwent immunotherapy-based multimodal treatments. Material and methods Unresectable stage III NSCLC patients treated by induction immunochemotherapy, concurrent chemoradiotherapy (CCRT) with or without consolidative immunotherapy from two prospective clinical trials were screened. Using the two-compartment Extend Tofts model, the parameters including K trans , K ep , V e , and V p were calculated from DCE-MRI data. The apparent diffusion coefficient was calculated from diffusion-weighted-MRI data. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to assess the predictive performance of MRI parameters. The Cox regression model was used for univariate and multivariate analysis.

Results

111 unresectable stage III NSCLC patients were enrolled. Patients received two cycles of induction immunochemotherapy and CCRT, with or without consolidative immunotherapy. With the median follow-up of 22.3 months, the median progression-free survival (PFS) and overall survival (OS) were 16.3 and 23.8 months. The multivariate analysis suggested that Eastern Cooperative Oncology Group score, TNM stage and the response to induction immunochemotherapy were significantly related to both PFS and OS. After induction immunochemotherapy, 67 patients (59.8%) achieved complete response or partial response and 44 patients (40.2%) had stable disease or progressive disease. The K trans of primary lung tumor before induction immunochemotherapy yielded the best performance in predicting the treatment response, with an AUC of 0.800. Patients were categorized into two groups: high-K trans group (n=67, K trans >164.3×10 −3 /min) and low-K trans group (n=44, K trans ≤164.3×10 −3 /min) based on the ROC analysis. The high-K trans group had a significantly higher objective response rate than the low-K trans group (85.1% (57/67) vs 22.7% (10/44), p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsImmunotherapyHumansFemaleMaleMiddle AgedAgedAdultMagnetic Resonance ImagingContrast MediaTreatment OutcomeInduction ChemotherapyNeoplasm StagingProspective Studies

Stichwörter der Autor:innen

Dynamic contrast-enhanced MRIKtransimmunotherapylung cancertreatment response

Substanzen

Contrast Media

Autor:innen und Institutionen

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cance…
  • Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicin…
  • United Imaging Healthcare, ShangHai, China.
  • United Imaging of Healthcare America, Houston, Texas, USA.
  • SuZhou TongDiao Company, Suzhou, China.
  • Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicin…

ORCID-Profile: Hui Liu

Zitieren

APA

Wang, D., Liu, S., Fu, J., Zhang, P., Zheng, S., Qiu, B., Liu, H., Ye, Y., Guo, J., Zhou, Y., Jiang, H., Yin, S., He, H., Xie, C., & Liu, H. (2024). Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy. Journal for ImmunoTherapy of Cancer, 12(6), e008574. https://doi.org/10.1136/jitc-2023-008574

Vancouver

Wang D, Liu S, Fu J, Zhang P, Zheng S, Qiu B, et al. Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy. Journal for ImmunoTherapy of Cancer. 2024;12(6):e008574. doi:10.1136/jitc-2023-008574

BibTeX
@article{Wang2024,
  author = {Wang, DaQuan and Liu, SongRan and Fu, Jia and Zhang, PengXin and Zheng, ShiYang and Qiu, Bo and Liu, Hui and Ye, YongQuan and Guo, JinYu and Zhou, Yin and Jiang, HaiHang and Yin, ShaoHan and He, HaoQiang and Xie, ChuanMiao and Liu, Hui},
  title = {Correlation of K trans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {6},
  pages = {e008574},
  doi = {10.1136/jitc-2023-008574}
}
Kostenlos starten →